Clinical Trial Update: Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of capecitabine and erlotinib in patients with metastatic colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Peter Kozuch | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED